Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 8/20 | 0.52 |
| ▸ | THRB | P10828 | 8/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | HTR1D | P28221 | 3/20 | 0.41 |
| ▸ | HTR1B | P28222 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6515493 | 0.99 | THRA (0.51) | THRATHRBS1PR1HTR1AHTR1D | |
| SCHEMBL6512502 | 0.98 | THRA (0.52) | THRATHRBS1PR1HTR1AHTR1D | |
| SCHEMBL6514037 | 0.96 | THRA (0.53) | THRATHRBS1PR1HTR1AHTR1D | |
| SCHEMBL6518378 | 0.94 | THRA (0.48) | THRATHRBS1PR1HTR1AHTR1D | |
| SCHEMBL6516494 | 0.94 | THRA (0.46) | THRATHRBS1PR1HTR1AHTR1D | |
| SCHEMBL6519233 | 0.94 | THRA (0.46) | THRATHRBS1PR1HTR1AHTR1D | |
| SCHEMBL6513907 | 0.93 | THRA (0.47) | THRATHRBS1PR1HTR1AHTR1D | |
| SCHEMBL6513360 | 0.93 | THRB (0.45) | THRATHRBS1PR1HTR1AHTR1D | |
| SCHEMBL6522125 | 0.93 | THRA (0.45) | THRATHRBS1PR1HTR1AHTR1D | |
| SCHEMBL6514142 | 0.92 | THRA (0.46) | THRATHRBS1PR1HTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 2005-02-10 | — | — | US | disclosed |
| US-6794406-B2 | FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20030078288-A1 | Indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078288-A1 | Indole derivatives | IDO1, IDO2, TPH2 | THRA 2460/4885THRB 1772/4885S1PR1 2318/4885 |
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | HMGCR, CYP46A1, EBP | THRA 1917/4885THRB 1835/4885S1PR1 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.